XML 43 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Research, Consulting and Supply Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Research Consulting And Supply Agreements |
Schedule of Research and Development Expenses | The Company’s research and development expenses were comprised of the following (thousands): Schedule of Research and Development Expenses
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Clinical studies |  | $ | 309 |  |  | $ | 582 |  |  | $ | 1,636 |  |  | $ | 1,880 |
Manufacturing & Engineering |  |  | 57 |  |  |  | 306 |  |  |  | 381 |  |  |  | 882 |
Quality control |  |  | 221 |  |  |  | 398 |  |  |  | 685 |  |  |  | 1,232 |
Regulatory |  |  | 20 |  |  |  | 151 |  |  |  | 159 |  |  |  | 539 |
Totals |  | $ | 607 |  |  | $ | 1,437 |  |  | $ | 2,861 |  |  | $ | 4,533 |
Costs incurred pursuant to the Amarex agreements were as follows (thousands):
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Pancreatic Cancer |  | $ | 3 |  |  | $ | 129 |  |  | $ | 199 |  |  | $ | 141 |
Post Covid Conditions |  |  | — |  |  |  | 28 |  |  |  | 8 |  |  |  | 196 |
Total |  | $ | 3 |  |  | $ | 157 |  |  | $ | 207 |  |  | $ | 337 |
Costs incurred pursuant to the Jubilant agreements were as follows (thousands):
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Total |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 1 |
Costs incurred pursuant to the Sterling Pharma agreements were as follows (thousands):
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Total |  | $ | — |  |  | $ | 133 |  |  | $ | — |  |  | $ | 262 |
Costs incurred pursuant to the Erasmus agreements were as follows (thousands):
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Total |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 79 |
Costs incurred pursuant to the Azenova agreements were as follows (thousands):
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Total |  | $ | — |  |  | $ | 50 |  |  | $ | — |  |  | $ | 230 |
Costs incurred pursuant to the Alcami agreements were as follows (thousands):
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three months ended September 30, |  |  | Nine months ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
research and development expenses |  | $ | (5 | ) |  | $ | — |  |  | $ | 10 |  |  | $ | 14 |

X
- References No definition available. + Details
Name: | AIMI_DisclosureResearchConsultingAndSupplyAgreementsAbstract
Namespace Prefix: | AIMI_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule Of ResearchAnd Development Expenses [Table Text Block] + References No definition available. + Details
Name: | AIMI_ScheduleOfResearchandDevelopmentExpensesTableTextBlock
Namespace Prefix: | AIMI_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration